Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Am Vet Med Assoc ; : 1-10, 2024 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-38906171

RESUMO

OBJECTIVE: To determine the rate of nodal metastasis in dogs with thyroid cancer and evaluate whether immunohistochemistry (IHC) identifies additional metastases beyond evaluation with H&E. ANIMALS: 70 prospectively enrolled client-owned dogs with thyroid cancer managed with thyroidectomy. METHODS: Dogs underwent thyroidectomy with concurrent elective bilateral medial retropharyngeal (MRP) ± deep cervical lymphadenectomy. Thyroid tumors and associated lymph nodes were reviewed by a single board-certified pathologist. Immunohistochemistry was used for all primary tumors (thyroid transcription factor-1 and calcitonin) to support a diagnosis of follicular or medullary carcinoma. Lymph nodes without evidence of metastasis after H&E review were labeled with the antibody associated with the wider uptake in the primary tumor. RESULTS: 77 thyroid cancers were resected from the 70 dogs enrolled, including 61 (79.2%) follicular, 8 (10.7%) medullary, and 7 (9.3%) mixed follicular/medullary carcinomas, with 1 (1.3%) carcinosarcoma. Twelve dogs had evidence of nodal metastasis following H&E review. Occult micrometastasis was identified in 1 dog following nodal IHC, resulting in documented metastasis in 13 of 70 (18.6%) dogs. Metastasis was more common with medullary (5/8) and follicular/medullary carcinoma (3/7) than follicular carcinoma (5/61). All MRP metastases were ipsilateral (7/77 [9.1%]), without contralateral MRP metastases (0/62). Fourteen of 41 (34.1%) deep cervical lymph nodes were metastatic. CLINICAL RELEVANCE: Nodal metastasis was uncommon for follicular carcinoma but was seen in > 50% of dogs with thyroid cancer involving a medullary component. Routine nodal IHC appears to be low yield for thyroid carcinoma. Extirpation of ipsilateral MRP and identifiable deep cervical lymph nodes is recommended with thyroidectomy until detailed preoperative risk stratification becomes available.

2.
Am J Physiol Renal Physiol ; 298(3): F807-17, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20032120

RESUMO

ANG II AT2 receptor (AT2R)-deficient mice exhibit abnormal ureteric bud (UB) budding, increased incidence of double ureters, and vesicoureteral reflux. However, the role of the AT2R during UB morphogenesis and the mechanisms by which aberrant AT2R signaling disrupts renal collecting system development have not been fully defined. In this study, we mapped the expression of the AT2R during mouse metanephric development, examined the impact of disrupted AT2R signaling on UB branching, cell proliferation, and survival, and investigated the cross talk of the AT2R with the glial-derived neurotrophic factor (GDNF)/c-Ret/Wnt11 signaling pathway. Embryonic mouse kidneys express AT2R in the branching UB and the mesenchyme. Treatment of embryonic day 12.5 (E12.5) metanephroi with the AT2R antagonist PD123319 or genetic inactivation of the AT2R in mice inhibits UB branching, decreasing the number of UB tips compared with control (34 +/- 1.0 vs. 43 +/- 0.6, P < 0.01; 36 +/- 1.8 vs. 48 +/- 1.3, P < 0.01, respectively). In contrast, treatment of metanephroi with the AT2R agonist CGP42112 increases the number of UB tips compared with control (48 +/- 1.8 vs. 39 +/- 12.3, P < 0.05). Using real-time quantitative RT-PCR and whole mount in situ hybridization, we demonstrate that PD123319 downregulates the expression of GDNF, c-Ret, Wnt11, and Spry1 mRNA levels in E12.5 metanephroi grown ex vivo. AT(2)R blockade or genetic inactivation of AT2R stimulates apoptosis and inhibits proliferation of the UB cells in vivo. We conclude that AT2R performs essential functions during UB branching morphogenesis via control of the GDNF/c-Ret/Wnt11 signaling pathway, UB cell proliferation, and survival.


Assuntos
Angiotensina II/metabolismo , Receptor Tipo 2 de Angiotensina/metabolismo , Ureter/embriologia , Proteínas Adaptadoras de Transdução de Sinal , Animais , Apoptose , Proliferação de Células , Sobrevivência Celular , Células Cultivadas , Regulação da Expressão Gênica no Desenvolvimento , Idade Gestacional , Fator Neurotrófico Derivado de Linhagem de Célula Glial/genética , Imidazóis/farmacologia , Imuno-Histoquímica , Hibridização In Situ , Proteínas de Membrana/genética , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Morfogênese , Mutação , Oligopeptídeos/farmacologia , Técnicas de Cultura de Órgãos , Fosfoproteínas/genética , Proteínas Proto-Oncogênicas c-ret/genética , Piridinas/farmacologia , RNA Mensageiro/metabolismo , Receptor Tipo 2 de Angiotensina/deficiência , Receptor Tipo 2 de Angiotensina/efeitos dos fármacos , Receptor Tipo 2 de Angiotensina/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transdução de Sinais , Ureter/efeitos dos fármacos , Ureter/metabolismo , Proteínas Wnt/genética
3.
Behav Pharmacol ; 20(8): 755-8, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19773645

RESUMO

Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.


Assuntos
Acetanilidas/administração & dosagem , Comportamento Animal/efeitos dos fármacos , Neuralgia/tratamento farmacológico , Piperazinas/administração & dosagem , Acetanilidas/farmacologia , Acetanilidas/uso terapêutico , Animais , Ataxia/induzido quimicamente , Temperatura Baixa , Avaliação Pré-Clínica de Medicamentos , Injeções Intraperitoneais , Injeções Subcutâneas , Masculino , Doenças do Sistema Nervoso/tratamento farmacológico , Doenças do Sistema Nervoso/fisiopatologia , Medição da Dor , Limiar da Dor/efeitos dos fármacos , Estimulação Física , Piperazinas/farmacologia , Piperazinas/uso terapêutico , Distribuição Aleatória , Ranolazina , Ratos , Ratos Sprague-Dawley , Tempo de Reação/efeitos dos fármacos , Bloqueadores dos Canais de Sódio/administração & dosagem , Bloqueadores dos Canais de Sódio/farmacologia , Bloqueadores dos Canais de Sódio/uso terapêutico
5.
Mech Dev ; 127(1-2): 21-7, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-19961928

RESUMO

The renin-angiotensin system (RAS) plays a critical role in ureteric bud (UB) and kidney morphogenesis. Mutations in the genes encoding components of the RAS cause a spectrum of congenital abnormalities of the kidney and urinary tract (CAKUT). However, the mechanisms by which aberrations in the RAS result in CAKUT are poorly understood. Given that c-Ret receptor tyrosine kinase (RTK) is a major inducer of UB branching, the present study tested the hypothesis that angiotensin (Ang) II-induced activation of c-Ret plays a critical role in UB branching morphogenesis. E12.5 mice metanephroi were grown for 24h in the presence or absence of Ang II, Ang II AT(1) receptor (AT(1)R) antagonist candesartan, phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 or ERK1/2 inhibitor PD98059. Ang II increased the number of UB tips (61+/-2.4 vs. 45+/-4.3, p<0.05) compared with control. Quantitative RT-PCR analysis demonstrated that Ang II increased c-Ret mRNA levels in the kidney (1.35+/-0.05 vs. 1.0+/-0, p<0.01) and in the UB cells (1.28+/-0.04 vs. 1.0+/-0, p<0.01) compared to control. This was accompanied by increased Tyr(1062)Ret phosphorylation by Ang II (5.5+/-0.9 vs. 1.8+/-0.4 relative units, p<0.05). In addition, treatment of UB cells with Ang II (10(-5)M) increased phosphorylation of Akt compared to control (213+/-16 vs. 100+/-20%, p<0.05). In contrast, treatment of metanephroi or UB cells with candesartan decreased c-Ret mRNA levels (0.72+/-0.06 vs. 1.0+/-0, p<0.01; 0.68+/-0.07 vs. 1.0+/-0, p<0.05, respectively) compared with control. Ang II-induced UB branching was abrogated by LY294002 (24+/-2.6 vs. 37+/-3.0, p<0.05) or PD98059 (33+/-2.0 vs. 48+/-2.2, p<0.01). These data demonstrate that Ang II-induced UB branching depends on activation of Akt and ERK1/2. We conclude that cross-talk between the RAS and c-Ret signaling plays an important role in the development of the renal collecting system.


Assuntos
Angiotensina II/metabolismo , Proteínas Proto-Oncogênicas c-ret/metabolismo , Ureter/embriologia , Animais , Cromonas/farmacologia , MAP Quinases Reguladas por Sinal Extracelular/antagonistas & inibidores , Flavonoides/farmacologia , Regulação da Expressão Gênica no Desenvolvimento , Camundongos , Morfolinas/farmacologia , Técnicas de Cultura de Órgãos/métodos , Fosfatidilinositol 3-Quinases/metabolismo , Sistema Renina-Angiotensina , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transdução de Sinais , Ureter/fisiologia , Proteínas ras/metabolismo
6.
J Am Chem Soc ; 127(12): 4254-9, 2005 Mar 30.
Artigo em Inglês | MEDLINE | ID: mdl-15783207

RESUMO

A novel electron microscopy specimen protocol shows that the presumed phospholipid bilayer membrane ribbons that wind helically to form the cylinders known as "tubules" are actually flattened tubes. These flattened tubes are alternatively found with a helical twist about the tube's long axis or occasionally flat with no winding or twist. Flat, cylindrically wound and axially twisted segments are routinely found along a single tube's length, and at the helically wound and axially twisted segment junctions, the chiral sense of the structure often, but not always, changes chiral sense.


Assuntos
Bicamadas Lipídicas/química , Fosfatidilcolinas/química , Di-Inos , Técnica de Fratura por Congelamento , Microscopia de Força Atômica , Microscopia Eletrônica de Varredura , Muramidase/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA